Regeneron Pharmaceuticals Inc - Asset Resilience Ratio
Regeneron Pharmaceuticals Inc (REGN) has an Asset Resilience Ratio of 14.17% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Regeneron Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check how strategically is Regeneron Pharmaceuticals Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Regeneron Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see REGN market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.79 Billion | 14.17% |
| Total Liquid Assets | $5.79 Billion | 14.17% |
Asset Resilience Insights
- Moderate Liquidity: Regeneron Pharmaceuticals Inc has 14.17% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Regeneron Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Regeneron Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Regeneron Pharmaceuticals Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Regeneron Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.53% | $5.49 Billion | $40.56 Billion | -3.75pp |
| 2024-12-31 | 17.28% | $6.52 Billion | $37.76 Billion | -7.25pp |
| 2023-12-31 | 24.53% | $8.11 Billion | $33.08 Billion | +8.66pp |
| 2022-12-31 | 15.87% | $4.64 Billion | $29.21 Billion | +4.83pp |
| 2021-12-31 | 11.04% | $2.81 Billion | $25.43 Billion | +2.93pp |
| 2020-12-31 | 8.12% | $1.39 Billion | $17.16 Billion | -2.67pp |
| 2019-12-31 | 10.78% | $1.60 Billion | $14.81 Billion | -0.65pp |
| 2018-12-31 | 11.44% | $1.34 Billion | $11.73 Billion | +4.63pp |
| 2017-12-31 | 6.81% | $596.85 Million | $8.76 Billion | -0.41pp |
| 2016-12-31 | 7.22% | $503.48 Million | $6.97 Billion | +3.01pp |
| 2015-12-31 | 4.21% | $236.12 Million | $5.61 Billion | -2.29pp |
| 2014-12-31 | 6.50% | $251.76 Million | $3.87 Billion | +1.14pp |
| 2013-12-31 | 5.37% | $158.38 Million | $2.95 Billion | +1.63pp |
| 2012-12-31 | 3.74% | $77.82 Million | $2.08 Billion | +0.47pp |
| 2011-12-31 | 3.27% | $43.33 Million | $1.32 Billion | -9.28pp |
| 2010-12-31 | 12.56% | $136.80 Million | $1.09 Billion | -5.56pp |
| 2009-12-31 | 18.11% | $134.25 Million | $741.20 Million | -15.76pp |
| 2008-12-31 | 33.87% | $226.95 Million | $670.04 Million | +5.30pp |
| 2007-12-31 | 28.57% | $267.53 Million | $936.26 Million | -9.27pp |
| 2006-12-31 | 37.84% | $221.40 Million | $585.09 Million | +10.91pp |
| 2005-12-31 | 26.93% | $114.04 Million | $423.50 Million | -14.24pp |
| 2004-12-31 | 41.16% | $194.75 Million | $473.11 Million | +4.57pp |
| 2003-12-31 | 36.59% | $175.49 Million | $479.56 Million | -10.45pp |
| 2002-12-31 | 47.04% | $184.19 Million | $391.57 Million | +19.25pp |
| 2001-12-31 | 27.79% | $137.69 Million | $495.40 Million | -13.80pp |
| 2000-12-31 | 41.60% | $86.63 Million | $208.27 Million | +10.57pp |
| 1999-12-31 | 31.02% | $42.50 Million | $137.00 Million | -- |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more